# Tiny Drug Carriers for Better Brain Tumor Treatment

> This patent describes super-small nanoparticle drug conjugates designed to sneak past barriers and spread evenly inside tough-to-treat tumors, especially in the brain, for more effective cancer therapy.

- **Patent:** US 20240408251
- **Original title:** Compositions and methods for targeted particle penetration, distribution, and response in malignant brain tumors
- **Owner:** Cornell University
- **Status:** Active
- **Times cited:** 0
- **Field:** biotech, pharmaceutical, nanotechnology, oncology, drug_delivery

## What it does

This patent describes a method for treating cancer using special tiny drug carriers called nanoparticle drug conjugates (NDCs). Each NDC has a nanoparticle, which is super small—no bigger than 20 nanometers in average diameter, and ideally between 3 to 8 nanometers (Claim 1, Claim 5). Attached to this nanoparticle is a 'linker-drug construct' where a drug is connected by a 'cleavable linker' (Claim 1). This linker can break apart, releasing the drug once it reaches the tumor (Claim 6). The key is that these NDCs are designed to easily spread and move around within the tumor tissue, called the 'tumor interstitium' (Claim 1). For example, these NDCs could carry a chemotherapy drug like gefitinib (Claim 9) directly into a glioblastoma multiforme (GBM) brain tumor (Claim 2), allowing the drug to reach more cancer cells effectively.

## What it does NOT cover

- Does not cover nanoparticle drug conjugates where the nanoparticle has an average diameter greater than 20 nanometers (Claim 1).
- Does not cover drug delivery systems where the drug is not attached to a nanoparticle via a cleavable linker (Claim 1).
- Does not cover methods of treating cancer that do not involve administering a nanoparticle drug conjugate designed to diffuse within tumor interstitium (Claim 1).
- Does not cover nanoparticles that are not specifically designed to carry a drug moiety (Claim 1).
- Does not cover treatments for conditions other than cancer (Claim 1).

## The clever bit

The truly clever part is the combination of extremely small nanoparticle size (under 20 nm, ideally 3-8 nm) with a cleavable drug linker, specifically designed to allow the entire drug-carrying nanoparticle to readily diffuse and spread widely within the dense, often difficult-to-penetrate tumor tissue (Claim 1, Claim 5). This ensures the drug reaches more cancer cells, rather than just the outer edges of the tumor.

## Real-world examples

1. Targeted chemotherapy for glioblastoma multiforme (GBM)
2. Drug delivery for metastatic brain tumors
3. Enhanced treatment for non-small cell lung carcinoma (NSCLC)
4. Theranostic agents combining diagnosis and therapy for brain cancer
5. Improved delivery of immunotherapies to tumor microenvironments

## Why it matters

Treating brain tumors is incredibly challenging because the brain has natural defenses, like the blood-brain barrier, that block most drugs. This patent addresses that problem by proposing extremely small nanoparticles that can potentially bypass these barriers and spread throughout the tumor more effectively (Claim 1). This improved distribution could mean that less drug is needed, and it reaches more cancer cells, leading to better outcomes for patients with aggressive cancers like glioblastoma (Claim 2). It also aims to treat 'leptomeningeal metastases,' which are cancers that spread to the fluid around the brain and spinal cord (Claim 4).

## Frequently asked questions

### What does Tiny Drug Carriers for Better Brain Tumor Treatment cover?

This patent describes super-small nanoparticle drug conjugates designed to sneak past barriers and spread evenly inside tough-to-treat tumors, especially in the brain, for more effective cancer therapy.

### Who owns patent US 20240408251?

This patent is owned by Cornell University.

### When does this patent expire?

This patent is expected to expire on December 19, 2043, when the invention enters the public domain.

### What problem does this patent solve?

Treating brain tumors is incredibly challenging because the brain has natural defenses, like the blood-brain barrier, that block most drugs. This patent addresses that problem by proposing extremely small nanoparticles that can potentially bypass these barriers and spread throughout the tumor more effectively (Claim 1). This improved distribution could mean that less drug is needed, and it reaches more cancer cells, leading to better outcomes for patients with aggressive cancers like glioblastoma (Claim 2). It also aims to treat 'leptomeningeal metastases,' which are cancers that spread to…

### What does this patent NOT cover?

Does not cover nanoparticle drug conjugates where the nanoparticle has an average diameter greater than 20 nanometers (Claim 1).

**Full plain-English explainer:** https://patentbrief.org/patent/us/20240408251/compositions-and-methods-for-targeted-particle-penetration-distribution-and-resp

**Original patent:** https://patents.google.com/patent/US20240408251

---

_Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._


## Related patents

Semantically similar inventions in the PatentBrief corpus:

- [How Special Nanoparticles Deliver Cancer Drugs Directly to Tumors](https://patentbrief.org/patent/us/20190046446/apo-e-modified-lipid-nanoparticles-for-drug-delivery-to-targeted-tissues-and-the) — This patent describes tiny fat-based particles, called lipid nanoparticles, designed to carry cancer drugs directly to tumor cells using a special protein (ApoE3) on their surface, avoiding a common, potentially problematic ingredient.
- [Targeting Drugs to Specific Body Tissues Using ApoE3-Coated Nanoparticles](https://patentbrief.org/patent/us/20190307892/targeted-drug-delivery-and-therapeutic-methods-using-apo-e-modified-lipid-nanopa) — This patent describes a method to deliver drugs or diagnostic agents precisely to target cells or tissues, including the brain, by packaging them inside tiny fat particles (lipid nanoparticles) coated with a special protein called ApoE3.
- [Tiny Packages for Delivering Gene-Targeting Drugs to Specific Cells](https://patentbrief.org/patent/us/10307490/lipid-nanoparticle-compositions-for-antisense-oligonucleotides-delivery) — This patent describes a method to create tiny, targeted packages made of lipids and proteins that can deliver specific gene-modifying drugs, like antisense oligonucleotides, directly to certain cells in the body.
- [Targeted Platinum Drugs for Cancer Treatment](https://patentbrief.org/patent/us/9884123/ligand-targeted-molecules-and-methods-thereof) — This patent describes a way to deliver platinum-based cancer drugs directly to tumor cells by attaching them to a special 'ligand' molecule that seeks out cancer cell markers.
- [Targeting Cancer with CAR T Cells Using a Chemical Tag](https://patentbrief.org/patent/us/20240165159/compositions-and-methods-for-car-t-cell-therapy) — This patent describes a method to treat cancer by giving a patient special immune cells (CAR T cells) that recognize a chemical tag, which is attached to a small drug molecule, along with a separate folate compound.
